Chinese food therapy |
|
|
Clinical Trial: Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
This study is currently recruiting patients.
Purpose
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving these drugs together with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well androgen suppression with either leuprolide or goserelin and either flutamide or bicalutamide together with radiation therapy works in treating patients with prostate cancer.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| adenocarcinoma of the prostate stage I prostate cancer stage II prostate cancer stage III prostate cancer | Drug: bicalutamide Drug: flutamide Drug: goserelin Drug: iodine I 125 Drug: leuprolide Drug: palladium Pd 103 Procedure: antiandrogen therapy Procedure: brachytherapy Procedure: endocrine therapy Procedure: hormone therapy Procedure: isotope therapy Procedure: neoadjuvant therapy Procedure: radiation therapy Procedure: releasing factor agonist therapy | Phase II |
MedlinePlus related topics: Prostate Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of Androgen-Suppression Therapy Combined With External-Beam Radiotherapy and Boost Brachytherapy in Patients With Intermediate-Risk Localized Prostate Cancer
OBJECTIVES:
- Determine the feasibility of androgen-suppression therapy combined with external-beam radiotherapy and boost brachytherapy (EBRT+BT) in patients with intermediate-risk localized prostate cancer.
- Determine the safety of EBRT+BT in these patients.
- Determine, in a preliminary manner, the efficacy of EBRT+BT in terms of rate of local recurrence at 5 years, time to prostate-specific antigen failure, and time to first rectal/bladder injury, in these patients.
OUTLINE: Patients receive either leuprolide intramuscularly or goserelin subcutaneously once every 12 weeks for a total of 24 weeks. Patients also receive either oral flutamide three times daily or oral bicalutamide once daily for 4 weeks.
Within 4 weeks after initiation of androgen-suppression therapy, patients undergo external-beam radiotherapy (EBRT) once daily, 5 days a week, for 5 weeks. At 2-4 weeks after completion of EBRT, patients undergo transrectal ultrasound-guided boost brachytherapy with implanted iodine I 125 or palladium Pd 103 seeds.
Patients are followed every 3 months for 2 years and then every 6 months for 4 years.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the prostate
- Must have one of the following prognostic factors:
- Stage T1-2, N0; prostate-specific antigen (PSA) ≤ 10 ng/mL; and Gleason score > 6
- Stage T1-2, N0; PSA > 10 ng/mL and < 20 ng/mL; and Gleason score ≤ 6
- Stage T3a, N0; PSA ≤ 10 ng/mL; and Gleason score ≤ 6
- Prostate volume < 60 cc by transrectal ultrasound
- No distant or nodal metastases
- No metastatic disease by bone scan, CT scan, or MRI
PATIENT CHARACTERISTICS: Age:
- 18 and over
Performance status:
- ECOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
Hepatic:
- Bilirubin ≤ 1.5 times upper limit of normal
Renal:
- Not specified
Other:
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY: Biologic therapy:
- No prior immunotherapy for prostate cancer
Chemotherapy:
- No prior chemotherapy for prostate cancer
Endocrine therapy:
- Prior androgen-suppression therapy for up to 4 weeks duration allowed if initiated within 4 weeks of study radiotherapy
- No other prior hormonal therapy
Radiotherapy:
- No prior radiotherapy for prostate cancer
Surgery:
- No prior surgery for prostate cancer
- No prior transurethral resection of the prostate
Other:
Location and Contact Information
Alabama
Northeast Alabama Regional Medical Center, Anniston, Alabama, 36207, United States; Recruiting
California
Naval Medical Center - San Diego, San Diego, California, 92134-3202, United States; Recruiting
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, 92093-0658, United States; Recruiting
UCSF Comprehensive Cancer Center, San Francisco, California, 94115, United States; Recruiting
Veterans Affairs Medical Center - San Diego, San Diego, California, 92161, United States; Recruiting
Veterans Affairs Medical Center - San Francisco, San Francisco, California, 94121, United States; Recruiting
Delaware
CCOP - Christiana Care Health Services, Newark, Delaware, 19713, United States; Recruiting
District of Columbia
Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, 20007, United States; Recruiting
Veterans Affairs Medical Center - Washington, DC, Washington, District of Columbia, 20422, United States; Recruiting
Walter Reed Army Medical Center, Washington, District of Columbia, 20307-5001, United States; Recruiting
Florida
Broward General Medical Center, Fort Lauderdale, Florida, 33316, United States; Recruiting
CCOP - Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States; Recruiting
Florida Hospital Cancer Institute, Orlando, Florida, 32804, United States; Recruiting
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, 33021, United States; Recruiting
Illinois
CCOP - Illinois Oncology Research Association, Peoria, Illinois, 61615-7828, United States; Recruiting
Louis A. Weiss Memorial Hospital, Chicago, Illinois, 60640, United States; Recruiting
University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States; Recruiting
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, 60612, United States; Recruiting
West Suburban Center for Cancer Care, River Forest, Illinois, 60305, United States; Recruiting
Indiana
Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne, Indiana, 46885-5099, United States; Recruiting
Iowa
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, 52242-1009, United States; Recruiting
Kentucky
Baptist Hospital East - Louisville, Louisville, Kentucky, 40207, United States; Recruiting
Maryland
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, 21201, United States; Recruiting
Massachusetts
Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States; Recruiting
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States; Recruiting
UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, 01655, United States; Recruiting
Michigan
Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph, Saint Joseph, Michigan, 49085, United States; Recruiting
Minnesota
University of Minnesota Cancer Center, Minneapolis, Minnesota, 55455, United States; Recruiting
Veterans Affairs Medical Center - Minneapolis, Minneapolis, Minnesota, 55417, United States; Recruiting
Missouri
CCOP - Kansas City, Kansas City, Missouri, 64131, United States; Recruiting
Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, 65203, United States; Recruiting
Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, 63110, United States; Recruiting
Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, 65201, United States; Recruiting
Nebraska
UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, 68198-7680, United States; Recruiting
Nevada
CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, 89106, United States; Recruiting
Veterans Affairs Medical Center - Las Vegas, Las Vegas, Nevada, 89106, United States; Recruiting
New Hampshire
New Hampshire Oncology-Hematology, PA - Hooksett, Hooksett, New Hampshire, 03106, United States; Recruiting
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756-0002, United States; Recruiting
New Jersey
Cancer Institute of New Jersey at the Cooper University Hospital, Camden, New Jersey, 08103, United States; Recruiting
New York
CCOP - North Shore University Hospital, Manhasset, New York, 11030, United States; Recruiting
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., East Syracuse, New York, 13057, United States; Recruiting
Elmhurst Hospital Center, Elmhurst, New York, 11373, United States; Recruiting
Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States; Recruiting
Mount Sinai Medical Center, New York, New York, 10029, United States; Recruiting
New York Weill Cornell Cancer Center at Cornell University, New York, New York, 10021, United States; Recruiting
North Shore University Hospital, Manhasset, New York, 11030, United States; Recruiting
Queens Cancer Center of Queens Hospital, Jamaica, New York, 11432, United States; Recruiting
Roswell Park Cancer Institute, Buffalo, New York, 14263-0001, United States; Recruiting
SUNY Upstate Medical University Hospital, Syracuse, New York, 13210, United States; Recruiting
Veterans Affairs Medical Center - Buffalo, Buffalo, New York, 14215, United States; Recruiting
Veterans Affairs Medical Center - Syracuse, Syracuse, New York, 13210, United States; Recruiting
North Carolina
Cape Fear Valley Medical Center, Fayetteville, North Carolina, 28302-2000, United States; Recruiting
CCOP - Southeast Cancer Control Consortium, Goldsboro, North Carolina, 27534-9479, United States; Recruiting
Comprehensive Cancer Center at Moore Regional Hospital, Pinehurst, North Carolina, 28374, United States; Recruiting
Comprehensive Cancer Center at Wake Forest University, Winston Salem, North Carolina, 27157-1082, United States; Recruiting
Duke Comprehensive Cancer Center, Durham, North Carolina, 27710, United States; Recruiting
Lenoir Memorial Cancer Center, Kinston, North Carolina, 28503-1678, United States; Recruiting
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, 27599-7295, United States; Recruiting
NorthEast Oncology Associates - Concord, Concord, North Carolina, 28025, United States; Recruiting
Veterans Affairs Medical Center - Asheville, Asheville, North Carolina, 28805-9913, United States; Recruiting
Veterans Affairs Medical Center - Durham, Durham, North Carolina, 27705, United States; Recruiting
Zimmer Cancer Center at New Hanover Regional Medical Center, Wilmington, North Carolina, 28402-9025, United States; Recruiting
Ohio
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, 43210-1240, United States; Recruiting
Oklahoma
Oklahoma University Medical Center, Oklahoma City, Oklahoma, 73104, United States; Recruiting
Rhode Island
Miriam Hospital at Lifespan, Providence, Rhode Island, 02906, United States; Recruiting
Texas
Veterans Affairs Medical Center - Dallas, Dallas, Texas, 75219, United States; Recruiting
Vermont
Green Mountain Oncology Group, Bennington, Vermont, 05201, United States; Recruiting
Vermont Cancer Center at University of Vermont, Burlington, Vermont, 05401-3498, United States; Recruiting
Virginia
Martha Jefferson Hospital, Charlottesville, Virginia, 22902, United States; Recruiting
MBCCOP - Massey Cancer Center, Richmond, Virginia, 23298-0037, United States; Recruiting
Oncology and Hematology Associates of Southwest Virginia, Incorporated - Roanoke, Roanoke, Virginia, 24014, United States; Recruiting
Virginia Oncology Associates - Norfolk, Norfolk, Virginia, 23502, United States; Recruiting
West Virginia
St. Mary's Medical Center, Huntington, West Virginia, 25701, United States; Recruiting
Mark Hurwitz, MD, Study Chair, Brigham and Women's Hospital
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Record last reviewed: February 2005
Last Updated: March 28, 2005
Record first received: October 4, 2000
ClinicalTrials.gov Identifier: NCT00006359
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005

Not Signed In -


